AZR-DEM-011

AZR-DEM-011 is a preclinical-stage new chemical entity (NCE) being developed by Azura Ophthalmics for the treatment of *Demodex* blepharitis. *Demodex* blepharitis is a common inflammatory condition of the eyelid margin caused by an infestation of *Demodex* mites, which can lead to irritation, redness, and meibomian gland dysfunction. While the specific molecular target and mechanism of action for AZR-DEM-011 have not been publicly disclosed, the program is part of Azura's specialized pipeline focusing on lid margin diseases. As an NCE, it represents a novel pharmacological approach to managing mite infestation or the associated clinical symptoms of blepharitis.